Examination of Glutamate and mGluR5 in Psychiatric Disorders (NCT02727972) | Clinical Trial Compass
CompletedNot Applicable
Examination of Glutamate and mGluR5 in Psychiatric Disorders
United States180 participantsStarted 2012-02-21
Plain-language summary
This research study is designed to look at the involvement of the glutamate system in depression. Each subject will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of one MRI scan, and PET scan. Subjects will also participate in cognitive testing. Depending on camera time, staff availability and subject schedule, total study participation may last 1-2 months.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
General inclusion criteria:
* Subjects will be between the ages of 18-70 years old
* English speaking
* No other DSM-5 diagnosis present, besides required as below
Inclusion criteria for acute depressed subjects:
* Clinical diagnosis of a current depressive episode
* Medication-free for at least 2 weeks or medicated with a permissible medication
Inclusion criteria for PTSD subjects:
* Clinical diagnosis of current PTSD as per DSM-5
* Medication free for at least 2 weeks or medicated with a permissible medication
Inclusion criteria for healthy controls:
* No current, or history of, any DSM-5 diagnosis
Exclusion Criteria:
* Have a current or past significant medical, neurological or metabolic disorder or head injury that lead to significant long term decline in cognitive abilities as seen by decline in grades or work performance
* Have significant medical illness such that would contraindicate study participation based on above criteria and PI/MD history review
* Have active, significant suicidal ideation
* Have implanted metallic devices or any MR contraindications
* Are women who are pregnant or breastfeeding
* Met DSM-5 criteria for mild substance use disorder (except nicotine and marijuana) within the past 6 months or met DSM-5 criteria for moderate to severe substance use disorder (except nicotine and marijuana) within the past year
* Have history of prior radiation exposure for research purposes within the past year such that participation in…
What they're measuring
1
Evidence of glutamate availability (mGluR5) in psychiatric disorders confirmed by MRI and PET data.
Timeframe: Through study completion date, an average of 4 years.